The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population

Basit Öğe Kaydı
dc.authoridkukul guven, fatma mutlu/0000-0003-3755-6021
dc.authoridAsgun, H. Fatih/0000-0002-8969-5886
dc.authoridsilan, coskun/0000-0002-8352-6571
dc.authoridgungor, buket/0000-0002-5802-1635
dc.contributor.authorSilan, Coskun
dc.contributor.authorDogan, Omer Tamer
dc.contributor.authorSilan, Fatma
dc.contributor.authorKukulguven, Fatma Mutlu
dc.contributor.authorAsgun, Halil Fatih
dc.contributor.authorOzdemir, Semra
dc.contributor.authorUludag, Ahmet
dc.date.accessioned2025-01-27T21:05:29Z
dc.date.available2025-01-27T21:05:29Z
dc.date.issued2012
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractThe aim was to investigate the prevalence of VKORC1 and CYP2C9 genotypes in patients requiring anticoagulant therapy in two different region's populations of Turkey. The recent cohort included 292 patients that needed anticoagulant therapy, and who had a history of deep vein thrombosis and/or pulmonary artery thromboembolism. Genomic DNA was isolated from peripheral blood samples and the StripAssay reverse hybridization or Real Time PCR technique was used for genotype analysis. Genotypes for CYP2C9 were detected as follows: 165 (56.5 %) for CYP2C9*1/*1, 67 (23.0 %) for CYP2C9*1/*2, 25 (8.6 %) for CYP2C9*1/*3, 9 (3.0 %) for CYP2C9*2/*2, 21 (7.2 %) for CYP2C9*2/*3, 5(1.7 %) for CYP2C9*3/*3 for CYP2C9 and the allele frequencies were: 0.723 for allele*1, 0.182 for allele*2 and 0.095 for allele*3 respectively. Genotypes for VKORC1 were detected as follows: 64 (21.9 %) for GG, 220 (75.4 %) for GA and 8 (2.7 %) for AA alleles. The G allele frequency was detected as 0.596, and the A allele frequency was 0.404. The VKORC1 1639 G > A and CYP2C9 mutation prevalence and allele frequency of the current results from two different populations (Sivas and Canakkale) showed similarly very variable profiles when compared to the other results from the Turkish population.
dc.identifier.doi10.1007/s11033-012-2004-2
dc.identifier.endpage11022
dc.identifier.issn0301-4851
dc.identifier.issn1573-4978
dc.identifier.issue12
dc.identifier.pmid23065265
dc.identifier.scopus2-s2.0-85027958881
dc.identifier.scopusqualityQ2
dc.identifier.startpage11017
dc.identifier.urihttps://doi.org/10.1007/s11033-012-2004-2
dc.identifier.urihttps://hdl.handle.net/20.500.12428/27667
dc.identifier.volume39
dc.identifier.wosWOS:000310586700120
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofMolecular Biology Reports
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectVKORC1 1639 G < A
dc.subjectCYP2C9*2 and*3 SNP
dc.subjectAnticoagulant therapy
dc.subjectAllele frequency
dc.subjectTurkish population
dc.titleThe prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu